Alumis logo

Alumis, Inc.

Biotechnology

Alumis Stock

Alumis is a clinical-stage biopharmaceutical company focused on developing oral precision therapies to transform the lives of patients with immune-mediated diseases. Its approach involves leveraging a precision analytics platform and deep expertise in precision medicine drug discovery, development, and immunology.

Founded: 2021

Alumis Website

For more Alumis stock information, or to buy or sell private shares, sign up for a MicroVentures account.

Management Team

Martin Babler President, Chief Executive Officer, and Chairman
Mark Bradley Chief Development Officer
Jörn Drappa, MD, Ph.D. Chief Medical Officer
David Goldstein Chief Scientific Officer
Roy Hardiman Chief Business and Legal Officer
John Schroer Chief Financial Officer

Funding Information